
Opinion|Videos|August 7, 2024
First-Line Immune Checkpoint Inhibitors for Poor Risk Metastatic RCC
Key opinion leaders in renal cell carcinoma provide a comprehensive overview of first-line immune checkpoint inhibitor combination regimens for patients with intermediate-to-poor risk metastatic renal cell carcinoma.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
2
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
3
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
4
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
5

















